<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Medicine (Baltimore)</journal-id><journal-id journal-id-type="iso-abbrev">Medicine (Baltimore)</journal-id><journal-id journal-id-type="publisher-id">MD</journal-id><journal-title-group><journal-title>Medicine</journal-title></journal-title-group><issn pub-type="ppub">0025-7974</issn><issn pub-type="epub">1536-5964</issn><publisher><publisher-name>Lippincott Williams &#x00026; Wilkins</publisher-name><publisher-loc>Hagerstown, MD</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40388796</article-id><article-id pub-id-type="pmc">PMC12091622</article-id>
<article-id pub-id-type="publisher-id">MD-D-24-08203</article-id><article-id pub-id-type="art-access-id">00077</article-id><article-id pub-id-type="doi">10.1097/MD.0000000000042015</article-id><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" article-version-type="Version of Record">3</article-version><article-categories><subj-group subj-group-type="heading"><subject>3700</subject></subj-group><subj-group><subject>Research Article</subject><subject>Bibliometric Review</subject></subj-group></article-categories><title-group><article-title>Bibliometric analysis of hepatocellular carcinoma and tyrosine kinase inhibitors</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Wurihan</given-names></name><degrees>MD</degrees><email>478842986@qq.com</email><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0002-6253-9338</contrib-id><name><surname>Mao</surname><given-names>Hejun</given-names></name><degrees>MD</degrees><email>2830747286@qq.com</email><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Song</surname><given-names>Jian</given-names></name><degrees>MD</degrees><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0007-4954-7620</contrib-id><name><surname>Yang</surname><given-names>Fan</given-names></name><degrees>MD</degrees><xref rid="aff2" ref-type="aff">b</xref><xref rid="c1" ref-type="corresp">*</xref></contrib><aff id="aff1"><label>a</label>Department of Neurology Department, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China</aff><aff id="aff2"><label>b</label>Department of Hepatobiliary Surgery, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China</aff><aff id="aff3"><label>c</label>Emergency Intensive Care Unit, Inner Mongolia Autonomous Region People&#x02019;s Hospital, Hohhot, China.</aff></contrib-group><author-notes><corresp id="c1"><label>*</label>Correspondence: Fan Yang, Department of Hepatobiliary Surgery, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia 010050, China (e-mail: <email xlink:href="yf_anhua@163.com">yf_anhua@163.com</email>).</corresp></author-notes><pub-date pub-type="collection"><day>16</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>16</day><month>5</month><year>2025</year></pub-date><volume>104</volume><issue>20</issue><elocation-id>e42015</elocation-id><history><date date-type="received"><day>20</day><month>7</month><year>2024</year></date><date date-type="received"><day>12</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>13</day><month>3</month><year>2025</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2025 the Author(s). Published by Wolters Kluwer Health, Inc.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License 4.0 (CCBY)</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="medi-104-e42015.pdf"/><abstract><sec><title>Background:</title><p>Hepatocellular carcinoma (HCC) is a common malignant tumor globally and in China, and its incidence and mortality rate are increasing year by year, and it faces many challenges and difficulties in treatment. Tyrosine kinase inhibitors (TKIs) have important roles in cell growth, proliferation, and differentiation, and have now become important drugs for cancer treatment. There are no bibliometric studies on liver cancer and TKIs to date.</p></sec><sec><title>Methods:</title><p>We retrieved 2848 records from the Web of Science&#x02122; Core Collection (WoSCC) database and analyzed them scientifically and metrically using CiteSpace and VOSviewer in terms of temporal and spatial distributions, author distributions, journal distributions, references, and keywords.</p></sec><sec><title>Results:</title><p>From January 1, 2004, to December 31, 2023, the WoSCC database documented 2848 publications related to tyrosinase inhibitors in HCC, comprising 2151 articles and 697 reviews. This literature involved 80 countries and regions, 3265 institutions, and 16,653 authors. Analysis shows a steady increase in publications annually since 2004, divided into 3 phases: 2004 to 2010 with fewer than 100 papers annually, suggesting minimal research attention; 2011 to 2019 with gradual growth, indicating increasing research interest; and a rapid surge post-2020, peaking in 2023, signaling heightened global interest in this field.</p></sec><sec><title>Conclusion:</title><p>Our bibliometric analysis on TKIs and HCC spans years, countries, institutions, authors, disciplines, and journals. Since 2004, this field has gained attention, with current research focusing on inflammatory and immune mechanisms, associated diseases, cytokines, and TKIs&#x02019; applications in liver cancer treatment, including combination therapies. These areas signify emerging research directions.</p></sec></abstract><kwd-group><kwd>bibliometric analysis</kwd><kwd>hepatocellular carcinoma</kwd><kwd>tyrosine kinase inhibitors</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>1. Introduction</title><p>Liver cancer is the 6th most common cancer in the world and has been a global challenge as one of the third most common tumors with a mortality rate after gastric and esophageal cancers. The World Health Organization has estimated that more than 1 million people will die of liver cancer in 2030 based on annual projections.<sup>[<xref rid="R1" ref-type="bibr">1</xref>]</sup> Hepatocellular carcinoma (HCC) is the most common pathological type of liver cancer, accounting for 75% of all liver cancers, and its occurrence is associated with a variety of liver diseases such as viral hepatitis, alcoholic and nonalcoholic fatty liver disease. Tumor growth is dependent on direct contact or paracellular effects related to tumor cells, immune cells, and vascular endothelial cells in the tumor microenvironment.<sup>[<xref rid="R2" ref-type="bibr">2</xref>]</sup> Traditional surgical resection, transcatheter arterial chemoembolization, percutaneous anhydrous ethanol injection, radiofrequency ablation therapy, and liver transplantation are the main treatment modalities for HCC,<sup>[<xref rid="R3" ref-type="bibr">3</xref>]</sup> and surgery is feasible to achieve a complete cure for early-stage HCC. Early-stage liver cancer can be treated with surgery to achieve a complete cure, but 70% of liver cancer patients have already progressed to the middle or late stage at the time of consultation, losing the opportunity for surgery.</p><p>With the development of molecular biology and immunology, molecularly targeted drugs such as multireceptor tyrosine kinase inhibitors (TKI) have gradually become one of the main approaches for the treatment of intermediate and advanced HCC in recent years.<sup>[<xref rid="R4" ref-type="bibr">4</xref>]</sup> Receptor tyrosine kinases (RTKs) are a group of transmembrane receptors characterized by their cytoplasmic region with intrinsic activity of tyrosine kinases (TKs). RTKs are expressed during prenatal and postnatal development of multicellular animals and play important roles in pathways such as cell survival, proliferation, differentiation, metabolism, regeneration, and cell death.<sup>[<xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R6" ref-type="bibr">6</xref>]</sup> The main targets of receptor TKIs are vascular endothelial growth factor receptor (VEGFR) 1 to 3, fibroblast growth factor receptor (FGFR) 1 to 4, platelet-derived growth factor receptor (FGFR) 1 to 4, platelet-derived growth factor &#x003b1;, c-Kit, RET, etc,<sup>[<xref rid="R7" ref-type="bibr">7</xref>]</sup> in addition to enhancing the infiltration of NK cells into the tumor and their cytotoxicity, and promoting the expression of cytotoxic factors in the tumor tissues and thus exerting antitumor activity.<sup>[<xref rid="R8" ref-type="bibr">8</xref>]</sup> In view of the multitargeted and multidirectional antitumor effects of multireceptor TKIs in HCC, combination therapy based on multireceptor TKIs has become the first choice for late-stage treatment, and also provides many new ideas for the treatment of HCC.<sup>[<xref rid="R9" ref-type="bibr">9</xref>]</sup></p><p>Bibliometrics is a branch of informatics that analyzes literature from a quantitative and qualitative perspective by studying the systematic and bibliometric characteristics of literature<sup>[<xref rid="R10" ref-type="bibr">10</xref>]</sup> to assess the status, trends, and frontiers of research activities<sup>[<xref rid="R10" ref-type="bibr">10</xref>&#x02013;<xref rid="R12" ref-type="bibr">12</xref>]</sup> This study retrieved bibliometric data (annual articles, countries/regions, authors, institutions, disciplines, journals, references, and keywords) on liver cancer and TKI research from various fields based on the Web of Science&#x02122; Core Collection (WoSCC), and descriptive statistics were analyzed. This paper discusses the current status, hotspots and cutting-edge literature of research on liver cancer and TKIs, and uses CiteSpace and VOSviewer to map the knowledge landscape to provide a reference for follow-up-related research.</p></sec><sec sec-type="methods"><title>2. Methods and materials</title><p>The WoSCC database has better accuracy in annotating literature types than any other database and is considered the best choice for literature analysis, so we chose to search in this database. We searched WOS on April 12, 2024, for all articles related to the use of tyrosinase inhibitors in HCC between 2004 and December 31, 2023, with the following search formula: ((((((TS=(Tyrosine Kinase Inhibitors)) OR TS=(Inhibitors, Tyrosine Kinase)) OR TS=(Kinase Inhibitors, Tyrosine)) OR TS=(Tyrosine Kinase Inhibitor)) OR TS=(TKI Tyrosine Kinase Inhibitors)) OR TS=(Tyrosine Protein Kinase Inhibitors)) OR TS=(TKI) AND (((((((((((((((((((((TS=(Liver Neoplasms)) OR TS=(Neoplasms, Hepatic)) OR TS=(Neoplasms, Liver)) OR TS=(Liver Neoplasm)) OR TS=(Neoplasm, Liver)) OR TS=(Hepatic Neoplasms)) OR TS=(Hepatic Neoplasm)) OR TS=(Neoplasm, Hepatic)) OR TS=(Cancer of Liver)) OR TS=(Hepatocellular Cancer)) OR TS=(Cancers, Hepatocellular)) OR TS=(Hepatocellular Cancers)) OR TS=(Hepatic Cancer)) OR TS=(Cancer, Hepatic)) OR TS=(Cancers, Hepatic)) OR TS=(Hepatic Cancers)) OR TS=(Liver Cancer)) OR TS=(Cancer, Liver)) OR TS=(Cancers, Liver)) OR TS=(Liver Cancers)) OR TS=(Cancer of the Liver)) OR TS=(Cancer, Hepatocellular). Literature screening for this study was based on the following inclusion criteria: (1) there were full-text publications related to the application of tyrosinase inhibitors in HCC; (2) the articles and review manuscript categories were written in English; and (3) the articles were published between January 1, 2004, and December 31, 2023. The exclusion criteria were as follows: (1) the topic was not related to tyrosinase inhibitors in HCC application; (2) the articles were conference abstracts, news, briefs, etc. Plain text versions of the papers were exported.</p><p>GraphPad Prism v8.0.2 was used to analyze and plot annual papers, national publication trends, and rates. In addition, CtieSpace (6.2.4R (64-bit) Advanced Edition) and VOSviewer (v.1.6.18) were used to analyze these data and visualize the scientific knowledge graph.</p><p>VOSviewer v.1.6.17, created by Van Eck and Waltman<sup>[<xref rid="R13" ref-type="bibr">13</xref>]</sup> in 2009, is a free JAVA-based software for analyzing large amounts of literature data and displaying it in a map format. To visualize the results of research in a particular field by mapping the co-citation network of literature, Professor Chaomei Chen created the CiteSpace (6.2.4R) software, which envisages the use of an experimental framework to study new concepts and evaluate existing technologies. This enables users to better understand the field of knowledge, research frontiers, and trends, and predict their future research progress.<sup>[<xref rid="R14" ref-type="bibr">14</xref>]</sup> Figure <xref rid="F1" ref-type="fig">1</xref> shows the search strategy and selection flowchart for this study.</p><fig position="float" id="F1"><label>Figure 1.</label><caption><p>Flowchart of literature search.</p></caption><graphic xlink:href="medi-104-e42015-g001" position="float"/></fig></sec><sec sec-type="results"><title>3. Results</title><p>The results showed that from January 1, 2004, to December 31, 2023, the WoSCC database contained 2848 publications on the use of tyrosinase inhibitors in HCC, including 2151 articles and 697 reviews. The literature involves 80 countries and regions, 3265 institutions, and 16,653 authors.</p><p>Since 2004, the number of papers published each year has slowly increased (Fig. <xref rid="F2" ref-type="fig">2</xref>). We divide it into 3 phases, 2004 to 2010 with a slow growth and less than 100 papers per year, which indicates that the field is not paid attention by researchers, 2011 to 2019 with a gradual increase in the number of papers, which indicates that the field gradually enters into the field of vision of researchers, and 2020 with a rapid increase in the number of papers after 2020 and reaching a peak in 2023, which indicates that the field receives wide attention after 2020. After 2020, the number of publications in this field increases rapidly and reaches a peak in 2023, indicating that this field is widely concerned after 2020.</p><fig position="float" id="F2"><label>Figure 2.</label><caption><p>Annual volume of publications.</p></caption><graphic xlink:href="medi-104-e42015-g002" position="float"/></fig><sec><title>3.1. Countries and institutions</title><p>Research on the application of tyrosinase inhibitors in liver cancer has been conducted in 80 countries and regions. Figures <xref rid="F3" ref-type="fig">3</xref> and <xref rid="F4" ref-type="fig">4</xref> show the annual publication volume of the top 10 countries in the past decade, and the top 5 countries in this field are China, the United States, Japan, Italy, and Germany. China and the United States accounted for 58.64% of the total number of publications, far exceeding other countries.</p><fig position="float" id="F3"><label>Figure 3.</label><caption><p>Line graph of national issuances.</p></caption><graphic xlink:href="medi-104-e42015-g003" position="float"/></fig><fig position="float" id="F4"><label>Figure 4.</label><caption><p>Heat map of national issuances.</p></caption><graphic xlink:href="medi-104-e42015-g004" position="float"/></fig><p>Among the top 10 countries/regions in terms of the number of published papers, the United States has 53,712 citations (Table <xref rid="T1" ref-type="table">1</xref>), which is far more than all other countries/regions, and its citation/publication ratio (67.14) ranks high among all countries, indicating that the quality of its published papers is generally high. China is the 1st country in terms of the number of publications (870) and ranks 2nd in terms of the number of citations (29,464), and its citation/publication ratio (33.87) is ranked at the back of the list. The collaborative network is shown in Figure <xref rid="F5" ref-type="fig">5</xref>, with close cooperation between China, the most productive country, and the USA. The United States cooperates closely with Italy, Germany, and the United Kingdom, while China cooperates even more closely with Japan, Korea, and Spain. China not only has a large number of publications and a high citation frequency but also has a centrality of 0.12, indicating that it is currently the leading country in this field.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>National communications scale.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Rank</th><th align="center" rowspan="1" colspan="1">Country/region</th><th align="center" rowspan="1" colspan="1">Article counts</th><th align="center" rowspan="1" colspan="1">Centrality</th><th align="center" rowspan="1" colspan="1">Percentage (%)</th><th align="center" rowspan="1" colspan="1">Citation</th><th align="center" rowspan="1" colspan="1">Citation per publication</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">China</td><td align="center" rowspan="1" colspan="1">870</td><td align="center" rowspan="1" colspan="1">0.12</td><td align="center" rowspan="1" colspan="1">30.55</td><td align="center" rowspan="1" colspan="1">29,464</td><td align="center" rowspan="1" colspan="1">33.87</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">USA</td><td align="center" rowspan="1" colspan="1">800</td><td align="center" rowspan="1" colspan="1">0.35</td><td align="center" rowspan="1" colspan="1">28.09</td><td align="center" rowspan="1" colspan="1">53,712</td><td align="center" rowspan="1" colspan="1">67.14</td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">Japan</td><td align="center" rowspan="1" colspan="1">280</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">9.83</td><td align="center" rowspan="1" colspan="1">19,541</td><td align="center" rowspan="1" colspan="1">69.79</td></tr><tr><td align="left" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">Italy</td><td align="center" rowspan="1" colspan="1">238</td><td align="center" rowspan="1" colspan="1">0.16</td><td align="center" rowspan="1" colspan="1">8.36</td><td align="center" rowspan="1" colspan="1">18,477</td><td align="center" rowspan="1" colspan="1">77.63</td></tr><tr><td align="left" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">Germany</td><td align="center" rowspan="1" colspan="1">232</td><td align="center" rowspan="1" colspan="1">0.1</td><td align="center" rowspan="1" colspan="1">8.15</td><td align="center" rowspan="1" colspan="1">16,805</td><td align="center" rowspan="1" colspan="1">72.44</td></tr><tr><td align="left" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">England</td><td align="center" rowspan="1" colspan="1">166</td><td align="center" rowspan="1" colspan="1">0.06</td><td align="center" rowspan="1" colspan="1">5.83</td><td align="center" rowspan="1" colspan="1">13,145</td><td align="center" rowspan="1" colspan="1">79.19</td></tr><tr><td align="left" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">France</td><td align="center" rowspan="1" colspan="1">138</td><td align="center" rowspan="1" colspan="1">0.05</td><td align="center" rowspan="1" colspan="1">4.85</td><td align="center" rowspan="1" colspan="1">13,975</td><td align="center" rowspan="1" colspan="1">101.27</td></tr><tr><td align="left" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">South Korea</td><td align="center" rowspan="1" colspan="1">113</td><td align="center" rowspan="1" colspan="1">0.02</td><td align="center" rowspan="1" colspan="1">3.97</td><td align="center" rowspan="1" colspan="1">9303</td><td align="center" rowspan="1" colspan="1">82.33</td></tr><tr><td align="left" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">Spain</td><td align="center" rowspan="1" colspan="1">103</td><td align="center" rowspan="1" colspan="1">0.07</td><td align="center" rowspan="1" colspan="1">3.62</td><td align="center" rowspan="1" colspan="1">10,142</td><td align="center" rowspan="1" colspan="1">98.47</td></tr><tr><td align="left" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">Canada</td><td align="center" rowspan="1" colspan="1">97</td><td align="center" rowspan="1" colspan="1">0.04</td><td align="center" rowspan="1" colspan="1">3.41</td><td align="center" rowspan="1" colspan="1">9624</td><td align="center" rowspan="1" colspan="1">99.22</td></tr></tbody></table></table-wrap><fig position="float" id="F5"><label>Figure 5.</label><caption><p>Country cooperation network diagram.</p></caption><graphic xlink:href="medi-104-e42015-g005" position="float"/></fig><p>A total of 3265 institutions systematically published articles on the use of tyrosinase inhibitors in HCC. Among the top 10 institutions in terms of publications, 4 were from the United States, 3 were from China, 2 were from France, and 1 was from Egypt (Table <xref rid="T2" ref-type="table">2</xref> and Fig. <xref rid="F6" ref-type="fig">6</xref>). The University of Texas System published the most literature (96 papers, 10,261 citations, and 106.89 citations/paper). Egyptian Knowledge Bank (76 papers, 1460 citations, and 19.21 citations/paper) ranked second, UTMD Anderson Cancer Center (74 papers, 7542 citations, and 101.92 citations/paper) ranked third, and Harvard University (73 papers, 10,795 citations, and 147.88 citations/paper) ranked fourth. After further analysis, we found that domestic and foreign institutions prefer to cooperate with their own domestic units, so we call for strengthening cooperation between domestic and foreign institutions and breaking academic barriers.</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Institutional issuance form.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Rank</th><th align="center" rowspan="1" colspan="1">Institution</th><th align="center" rowspan="1" colspan="1">Country</th><th align="center" rowspan="1" colspan="1">Number of studies</th><th align="center" rowspan="1" colspan="1">Total citations</th><th align="center" rowspan="1" colspan="1">Average citation</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">University of Texas System</td><td align="center" rowspan="1" colspan="1">USA</td><td align="center" rowspan="1" colspan="1">96</td><td align="center" rowspan="1" colspan="1">10,261</td><td align="center" rowspan="1" colspan="1">106.89</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">Egyptian Knowledge Bank (EKB)</td><td align="center" rowspan="1" colspan="1">Egypt</td><td align="center" rowspan="1" colspan="1">76</td><td align="center" rowspan="1" colspan="1">1460</td><td align="center" rowspan="1" colspan="1">19.21</td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">UTMD Anderson Cancer Center</td><td align="center" rowspan="1" colspan="1">USA</td><td align="center" rowspan="1" colspan="1">74</td><td align="center" rowspan="1" colspan="1">7542</td><td align="center" rowspan="1" colspan="1">101.92</td></tr><tr><td align="left" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">Harvard University</td><td align="center" rowspan="1" colspan="1">USA</td><td align="center" rowspan="1" colspan="1">73</td><td align="center" rowspan="1" colspan="1">10,795</td><td align="center" rowspan="1" colspan="1">147.88</td></tr><tr><td align="left" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">University of California System</td><td align="center" rowspan="1" colspan="1">USA</td><td align="center" rowspan="1" colspan="1">70</td><td align="center" rowspan="1" colspan="1">6274</td><td align="center" rowspan="1" colspan="1">89.63</td></tr><tr><td align="left" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">Institut National de la Sante et de la Recherche Medicale (Inserm)</td><td align="center" rowspan="1" colspan="1">France</td><td align="center" rowspan="1" colspan="1">58</td><td align="center" rowspan="1" colspan="1">4774</td><td align="center" rowspan="1" colspan="1">82.31</td></tr><tr><td align="left" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">National China University</td><td align="center" rowspan="1" colspan="1">China</td><td align="center" rowspan="1" colspan="1">53</td><td align="center" rowspan="1" colspan="1">3940</td><td align="center" rowspan="1" colspan="1">74.34</td></tr><tr><td align="left" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">Sun Yat Sen University</td><td align="center" rowspan="1" colspan="1">China</td><td align="center" rowspan="1" colspan="1">51</td><td align="center" rowspan="1" colspan="1">2458</td><td align="center" rowspan="1" colspan="1">48.20</td></tr><tr><td align="left" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">Fudan University</td><td align="center" rowspan="1" colspan="1">China</td><td align="center" rowspan="1" colspan="1">47</td><td align="center" rowspan="1" colspan="1">1084</td><td align="center" rowspan="1" colspan="1">23.06</td></tr><tr><td align="left" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">Assistance Publique Hopitaux Paris (APHP)</td><td align="center" rowspan="1" colspan="1">France</td><td align="center" rowspan="1" colspan="1">43</td><td align="center" rowspan="1" colspan="1">4706</td><td align="center" rowspan="1" colspan="1">109.44</td></tr></tbody></table></table-wrap><fig position="float" id="F6"><label>Figure 6.</label><caption><p>Institutional collaborative network map.</p></caption><graphic xlink:href="medi-104-e42015-g006" position="float"/></fig></sec><sec><title>3.2. Journals</title><p>The top 10 most productive and cited journals are listed in Tables <xref rid="T3" ref-type="table">3</xref> and <xref rid="T4" ref-type="table">4</xref>. Figure <xref rid="F7" ref-type="fig">7</xref> shows the density statistics of magazine circulation. Cancers (79 articles, 2.77%) is the most published journal in the field, followed by Frontiers in Oncology (67 articles, 2.35%), Clinical Cancer Research (47 articles, 1.65%), and Oncotarget (41 articles, 1.44%). Among the top 10 most prolific journals, Clinical Cancer Research had the highest IF of 11.5. A total of 90% of these journals were classified in Q1 or Q2.</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Scale of magazine publications.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Rank</th><th align="center" rowspan="1" colspan="1">Journal</th><th align="center" rowspan="1" colspan="1">Article counts</th><th align="center" rowspan="1" colspan="1">Percentage (2848)</th><th align="center" rowspan="1" colspan="1">IF</th><th align="center" rowspan="1" colspan="1">Quartile in category</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">Cancers</td><td align="center" rowspan="1" colspan="1">79</td><td align="center" rowspan="1" colspan="1">2.77</td><td align="center" rowspan="1" colspan="1">5.2</td><td align="center" rowspan="1" colspan="1">Q2</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">Frontiers in Oncology</td><td align="center" rowspan="1" colspan="1">67</td><td align="center" rowspan="1" colspan="1">2.35</td><td align="center" rowspan="1" colspan="1">4.7</td><td align="center" rowspan="1" colspan="1">Q2</td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">Clinical Cancer Research</td><td align="center" rowspan="1" colspan="1">47</td><td align="center" rowspan="1" colspan="1">1.65</td><td align="center" rowspan="1" colspan="1">11.5</td><td align="center" rowspan="1" colspan="1">Q1</td></tr><tr><td align="left" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">Oncotarget</td><td align="center" rowspan="1" colspan="1">41</td><td align="center" rowspan="1" colspan="1">1.44</td><td align="center" rowspan="1" colspan="1">5.1</td><td align="center" rowspan="1" colspan="1">Q2</td></tr><tr><td align="left" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">Plos One</td><td align="center" rowspan="1" colspan="1">41</td><td align="center" rowspan="1" colspan="1">1.44</td><td align="center" rowspan="1" colspan="1">3.7</td><td align="center" rowspan="1" colspan="1">Q2</td></tr><tr><td align="left" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">Molecular Cancer Therapeutics</td><td align="center" rowspan="1" colspan="1">34</td><td align="center" rowspan="1" colspan="1">1.19</td><td align="center" rowspan="1" colspan="1">5.7</td><td align="center" rowspan="1" colspan="1">Q2</td></tr><tr><td align="left" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">BMC Cancer</td><td align="center" rowspan="1" colspan="1">32</td><td align="center" rowspan="1" colspan="1">1.12</td><td align="center" rowspan="1" colspan="1">3.8</td><td align="center" rowspan="1" colspan="1">Q2</td></tr><tr><td align="left" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">Cancer Chemotherapy and Pharmacology</td><td align="center" rowspan="1" colspan="1">32</td><td align="center" rowspan="1" colspan="1">1.12</td><td align="center" rowspan="1" colspan="1">3.0</td><td align="center" rowspan="1" colspan="1">Q3</td></tr><tr><td align="left" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">International Journal of Molecular Sciences</td><td align="center" rowspan="1" colspan="1">32</td><td align="center" rowspan="1" colspan="1">1.12</td><td align="center" rowspan="1" colspan="1">5.6</td><td align="center" rowspan="1" colspan="1">Q1</td></tr><tr><td align="left" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">Frontiers in Pharmacology</td><td align="center" rowspan="1" colspan="1">31</td><td align="center" rowspan="1" colspan="1">1.09</td><td align="center" rowspan="1" colspan="1">5.6</td><td align="center" rowspan="1" colspan="1">Q1</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>Journal co-citation table.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Rank</th><th align="center" rowspan="1" colspan="1">Cited Journal</th><th align="center" rowspan="1" colspan="1">Co-Citation</th><th align="center" rowspan="1" colspan="1">IF (2022)</th><th align="center" rowspan="1" colspan="1">Quartile in category</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">J Clin Oncol</td><td align="center" rowspan="1" colspan="1">1833</td><td align="center" rowspan="1" colspan="1">45.4</td><td align="center" rowspan="1" colspan="1">Q1</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">Clin Cancer Res</td><td align="center" rowspan="1" colspan="1">1820</td><td align="center" rowspan="1" colspan="1">11.5</td><td align="center" rowspan="1" colspan="1">Q1</td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">New Engl J Med</td><td align="center" rowspan="1" colspan="1">1688</td><td align="center" rowspan="1" colspan="1">158.5</td><td align="center" rowspan="1" colspan="1">Q1</td></tr><tr><td align="left" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">Cancer Res</td><td align="center" rowspan="1" colspan="1">1616</td><td align="center" rowspan="1" colspan="1">11.2</td><td align="center" rowspan="1" colspan="1">Q1</td></tr><tr><td align="left" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">Lancet Oncol</td><td align="center" rowspan="1" colspan="1">1166</td><td align="center" rowspan="1" colspan="1">51.1</td><td align="center" rowspan="1" colspan="1">Q1</td></tr><tr><td align="left" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">Ann Oncol</td><td align="center" rowspan="1" colspan="1">1058</td><td align="center" rowspan="1" colspan="1">50.5</td><td align="center" rowspan="1" colspan="1">Q1</td></tr><tr><td align="left" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">Lancet</td><td align="center" rowspan="1" colspan="1">1051</td><td align="center" rowspan="1" colspan="1">168.9</td><td align="center" rowspan="1" colspan="1">Q2</td></tr><tr><td align="left" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">Brit J Cancer</td><td align="center" rowspan="1" colspan="1">1036</td><td align="center" rowspan="1" colspan="1">8.8</td><td align="center" rowspan="1" colspan="1">Q1</td></tr><tr><td align="left" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">Oncogene</td><td align="center" rowspan="1" colspan="1">975</td><td align="center" rowspan="1" colspan="1">8.0</td><td align="center" rowspan="1" colspan="1">Q1</td></tr><tr><td align="left" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">Hepatology</td><td align="center" rowspan="1" colspan="1">966</td><td align="center" rowspan="1" colspan="1">14.0</td><td align="center" rowspan="1" colspan="1">Q1</td></tr></tbody></table></table-wrap><fig position="float" id="F7"><label>Figure 7.</label><caption><p>Density map of magazine issuance.</p></caption><graphic xlink:href="medi-104-e42015-g007" position="float"/></fig><p>Journal impact is determined by how often it is co-cited, which indicates whether the journal has had a significant impact on the scientific community. According to Figure <xref rid="F8" ref-type="fig">8</xref> and Table <xref rid="T4" ref-type="table">4</xref>, the journal with the highest number of co-citations is J Clin Oncol (1833), followed by Clin Cancer Res (1820), and New Engl J Med (1688). Among the top 10 most co-cited journals, Lancet was cited 1051 times with the highest IF among the top 10 journals (168.9). Of the journals that were co-cited, 60% of the journals were in the Q1/Q2 region.</p><fig position="float" id="F8"><label>Figure 8.</label><caption><p>Journal co-citation network diagram.</p></caption><graphic xlink:href="medi-104-e42015-g008" position="float"/></fig><p>The thematic distribution of academic publications is shown by a double map overlay (Fig. <xref rid="F9" ref-type="fig">9</xref>). Colored tracks indicate citation links, with citing journals on the left and cited journals on the right. Based on the displayed results, we identified 4 main colored citation paths, that is, studies published in journals in the field of molecular/biology/immunology were mainly cited by studies published in journals in the fields of molecular/biology/genetics and health/nursing/medicine, while studies published in journals in the field of medicine/medical/clinical were mainly cited by studies published in journals in the fields of molecular/biology/genetics and health/nursing/medicine.</p><fig position="float" id="F9"><label>Figure 9.</label><caption><p>Double-stacked map of journals.</p></caption><graphic xlink:href="medi-104-e42015-g009" position="float"/></fig></sec><sec><title>3.3. Authors and co-citing authors</title><p>Of all the authors who have published literature related to the use of tyrosinase inhibitors in HCC, the top 10 authors who have published the most papers are listed in Table <xref rid="T5" ref-type="table">5</xref>. The top 10 authors published a total of 129 papers, which is 4.53% of all the papers in the field. Attwa MW published the most research papers with 20 papers, followed by Kadi AA (19 papers), Cheng AL (15 papers), and Kudo M (14 papers). Further analysis showed that 5 of the top 10 authors were from China, 3 from Saudi Arabia, 1 from Japan, and 1 from Spain. CiteSpace visualized the network between authors (Fig. <xref rid="F10" ref-type="fig">10</xref>).</p><table-wrap position="float" id="T5"><label>Table 5</label><caption><p>Table of author publications and co-citations.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Rank</th><th align="center" rowspan="1" colspan="1">Author</th><th align="center" rowspan="1" colspan="1">Count</th><th align="center" rowspan="1" colspan="1">Location</th><th align="center" rowspan="1" colspan="1">Rank</th><th align="center" rowspan="1" colspan="1">Co-cited author</th><th align="center" rowspan="1" colspan="1">Citation</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">Attwa MW</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">Saudi Arabia</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">Llovet JM</td><td align="center" rowspan="1" colspan="1">726</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">Kadi AA</td><td align="center" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">Saudi Arabia</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">Kudo M</td><td align="center" rowspan="1" colspan="1">411</td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">Cheng AL</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">China</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">Bruix J</td><td align="center" rowspan="1" colspan="1">386</td></tr><tr><td align="left" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">Kudo M</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">Japan</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">Zhu AX</td><td align="center" rowspan="1" colspan="1">378</td></tr><tr><td align="left" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">Zhang L</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">China</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">Cheng AL</td><td align="center" rowspan="1" colspan="1">376</td></tr><tr><td align="left" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">Chen KF</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">China</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">Abou-Alfa GK</td><td align="center" rowspan="1" colspan="1">329</td></tr><tr><td align="left" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">Darwish HW</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">Saudi Arabia</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">Finn RS</td><td align="center" rowspan="1" colspan="1">311</td></tr><tr><td align="left" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">Marin JJG</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">Spain</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">Wilhelm SM</td><td align="center" rowspan="1" colspan="1">242</td></tr><tr><td align="left" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">Zhu AX</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">China</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">Jemal A</td><td align="center" rowspan="1" colspan="1">225</td></tr><tr><td align="left" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">Feng JF</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">China</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">Motzer RJ</td><td align="center" rowspan="1" colspan="1">220</td></tr></tbody></table></table-wrap><fig position="float" id="F10"><label>Figure 10.</label><caption><p>Author collaboration network.</p></caption><graphic xlink:href="medi-104-e42015-g010" position="float"/></fig><p>Figure <xref rid="F11" ref-type="fig">11</xref> and Table <xref rid="T5" ref-type="table">5</xref> show the top 10 authors with the highest number of co-citations and citations, respectively. Ninety-three authors were cited more than 20 times in total, indicating the high reputation and impact of their research. The largest nodes are associated with the most co-cited authors, including Llovet JM (726 citations), Kudo M (411 citations), and Bruix J (386 citations).</p><fig position="float" id="F11"><label>Figure 11.</label><caption><p>Author co-citation network map.</p></caption><graphic xlink:href="medi-104-e42015-g011" position="float"/></fig></sec><sec><title>3.4. Co-cited references</title><p>Taking a 1-year time slice with a time horizon of 2004 to 2023, the co-cited references network has 1421 nodes and 6183 links (Fig. <xref rid="F12" ref-type="fig">12</xref>). According to the top 10 most co-cited articles (Table <xref rid="T6" ref-type="table">6</xref>), LANCET&#x02019;s &#x0201c; Lenvatinib versus sorafenib in first-line treatment of patients with unresectable HCC: a randomized phase 3 noninferiority trial,&#x0201d; the first author of the article is Kudo M, which is based on a phase 2 trial in which levatinib, an inhibitor of VEGFR 1 to 3, FGFR 1 to 4, PDGF receptor a, RET and KIT, showed activity against HCC. This was an open-label, phase 3, multicenter, noninferiority trial that enrolled patients with unresectable HCC who had not received advanced treatment at 154 sites in 20 countries across Asia-Pacific, Europe, and North America. Patients were randomly assigned (1:1) via an interactive voice-to-web response system&#x02014;with region, gross portal vein invasion, extrahepatic spread or both, Eastern Cooperative Oncology Group performance status and body weight as stratification factors&#x02014;to receive oral lenvatinib (12&#x02009;mg/day for those weighing greater than or equal to 60&#x02009;kg and 8&#x02009;mg/day for those weighing less than 60&#x02009;kg) or sorafenib 400&#x02009;mg twice daily The cycle was 28 days. The primary endpoint was overall survival (OS) from the date of randomization to the date of death from any cause. Efficacy analyses followed the intention-to-treat principle, and only patients who received treatment were included in safety analyses. The noninferiority margin was set at 1.08. A total of 1492 patients were recruited between March 1, 2013, and July 30, 2015. A total of 954 eligible patients were randomly assigned to lenvatinib (478) or sorafenib (476). The median survival time for lenvatinib was 13.6 months (95% CI: 12.1&#x02013;14.9), which was not inferior to sorafenib (12.3 months, 10.4&#x02013;13.9; hazard ratio 0.92, 95% CI: 0.79&#x02013;1.06) and met the criterion for noninferiority. The most common adverse events of any grade with lenvatinib were hypertension (201 [42%]), diarrhea (184 [39%]), decreased appetite (162 [34%]), and weight loss (147 [31%]); the most common adverse events of any grade with sorafenib were palmoplantar erythromelalgia (249 [52%]), diarrhea (220 [46%]), hypertension (144 [30%]), and decreased appetite (127 [27%]).<sup>[<xref rid="R15" ref-type="bibr">15</xref>]</sup></p><table-wrap position="float" id="T6"><label>Table 6</label><caption><p>Co-cited literature table.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Rank</th><th align="center" rowspan="1" colspan="1">Title</th><th align="center" rowspan="1" colspan="1">Journal</th><th align="center" rowspan="1" colspan="1">Author(s)</th><th align="center" rowspan="1" colspan="1">Total citations</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomized phase 3 non-inferiority trial</td><td align="center" rowspan="1" colspan="1">Lancet</td><td align="center" rowspan="1" colspan="1">Kudo M</td><td align="center" rowspan="1" colspan="1">298</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomized, double-blind, placebo-controlled, phase 3 trial</td><td align="center" rowspan="1" colspan="1">Lancet</td><td align="center" rowspan="1" colspan="1">Bruix J</td><td align="center" rowspan="1" colspan="1">201</td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma</td><td align="center" rowspan="1" colspan="1">New England Journal of Medicine</td><td align="center" rowspan="1" colspan="1">Finn RS</td><td align="center" rowspan="1" colspan="1">196</td></tr><tr><td align="left" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma</td><td align="center" rowspan="1" colspan="1">New England Journal of Medicine</td><td align="center" rowspan="1" colspan="1">Abou-Alfa GK</td><td align="center" rowspan="1" colspan="1">177</td></tr><tr><td align="left" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial</td><td align="center" rowspan="1" colspan="1">Lancet</td><td align="center" rowspan="1" colspan="1">El-Khoueiry AB</td><td align="center" rowspan="1" colspan="1">146</td></tr><tr><td align="left" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomized, open-label phase 2 trial</td><td align="center" rowspan="1" colspan="1">Lancet Oncology</td><td align="center" rowspan="1" colspan="1">Zhu AX</td><td align="center" rowspan="1" colspan="1">140</td></tr><tr><td align="left" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased &#x003b1;-fetoprotein concentrations (REACH-2): a randomized, double-blind, placebo-controlled, phase 3 trial</td><td align="center" rowspan="1" colspan="1">Lancet Oncology</td><td align="center" rowspan="1" colspan="1">Zhu AX</td><td align="center" rowspan="1" colspan="1">113</td></tr><tr><td align="left" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial</td><td align="center" rowspan="1" colspan="1">Journal of Clinical Oncology</td><td align="center" rowspan="1" colspan="1">Finn RS</td><td align="center" rowspan="1" colspan="1">108</td></tr><tr><td align="left" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">Sorafenib in advanced hepatocellular carcinoma</td><td align="center" rowspan="1" colspan="1">New England Journal of Medicine</td><td align="center" rowspan="1" colspan="1">Llovet JM</td><td align="center" rowspan="1" colspan="1">103</td></tr><tr><td align="left" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma</td><td align="center" rowspan="1" colspan="1">Journal of Hepatology</td><td align="center" rowspan="1" colspan="1">European Assoc Study Liver</td><td align="center" rowspan="1" colspan="1">89</td></tr></tbody></table></table-wrap><fig position="float" id="F12"><label>Figure 12.</label><caption><p>Network diagram of co-cited literature.</p></caption><graphic xlink:href="medi-104-e42015-g012" position="float"/></fig><p>The second highest was published in LANCET, &#x0201c;Regorafenib for patients with HCC who progressed on sorafenib treatment (RESORCE): a randomized, double-blind, placebo-controlled, phase 3 trial,&#x0201d; authored by Bruix J, which argues that in the context of no systemic treatment currently available for patients with HCC whose disease progressed on sorafenib treatment, the study is a good example of how to improve the quality of care for patients with HCC. We aimed to evaluate the efficacy and safety of regorafenib in patients with HCC whose disease progressed during sorafenib treatment. In this randomized, double-blind, parallel-group, phase 3 trial, 152 sites in 21 countries recruited adult patients with HCC who were able to tolerate sorafenib (&#x02265;400&#x02009;mg/day for &#x02265;20 days during the last 28 days of treatment), whose disease progressed during sorafenib treatment and who had Child-Pugh A liver function. Using a computer-generated randomization list and an interactive voice response system, and based on geographic region, Eastern Cooperative Oncology Group performance status, macrovascular invasion, extrahepatic disease, and alpha-fetoprotein levels, the researchers randomly assigned participants (2:1) to optimal supportive care plus oral regorafenib 160&#x02009;mg or placebo once daily during weeks 1 to 3 of each 4-week cycle. Investigators, patients, and funders were unaware of the treatment assignment. The primary endpoint was OS (defined as the time from random allocation to death from any cause) and was analyzed by intention to treat. The trial is registered with <ext-link xlink:href="https://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link> as NCT01774344. Between May 14, 2013, and December 31, 2015, 843 patients were screened, of whom 573 were enrolled and randomly assigned (379 received regorafenib and 194 received placebo; efficacy analyzed population), and 567 started treatment (374 treated with regorafenib and 193 with placebo; safety analysis population). Regorafenib improved OS with a hazard ratio of 0.63 (95% CI: 0.50&#x02013;0.79; one-sided <italic toggle="yes">P</italic>&#x02005;&#x0003c;&#x02005;.0001); median survival was 10.6 months (95% CI: 9.1&#x02013;12.1) for regorafenib versus 7.8 months (6.3&#x02013;8.8) for placebo. Adverse events were reported in all regorafenib subjects (374 of 374 [100%]) and 179 of 193 placebo subjects (93%). The most common clinically relevant grade 3 or 4 treatment emergencies were hypertension (57 patients [15%] in the regorafenib group vs 9 patients [5%] in the placebo group), skin reactions of the hands and feet (47 patients [13%] vs 1 patient [1%]), fatigue (34 patients [9%] vs 9 patients [5%]), and diarrhea (12 patients [3%] vs none). Of the 88 deaths (grade 5 adverse events) reported during the study period (50 patients [13%] treated with regorafenib and 38 patients [20%] treated with placebo), the investigators attributed 7 (2%) in the regorafenib group and 2 (1%) in the placebo group to the study medication, with hepatic failure occurring in 2 patients (1%) in the placebo group. Regorafenib is the only systemic therapy that provides a survival benefit for patients with HCC whose disease has progressed after sorafenib treatment. Future trials should explore combinations of regorafenib with other systemic agents, as well as third-line therapy for patients who have failed or are intolerant to sorafenib and regorafenib.<sup>[<xref rid="R16" ref-type="bibr">16</xref>]</sup></p><p>We performed co-citation reference clustering and temporal clustering analyses (Figs. <xref rid="F13" ref-type="fig">13</xref> and <xref rid="F14" ref-type="fig">14</xref>). We found that angiogenesis (cluster1), gefitinib (cluster4), c-met proto-oncogene (cluster9), and apoptosis (cluster11) were early research hotspots. Sorafenib (cluster2), meta-analysis (cluster3), hgf (cluster6), fgf (cluster13), and panitumumab (cluster14) are hotspots for mid-stage research. Immunotherapy (cluster0), lenvatinib (cluster5), tumor microenvironment (cluster7), nonsmall cell lung cancer (cluster8), apatinib (cluster10), human liver microsomes (cluster12), cabozantinib (cluster15), intrahepatc cholangiocarcinoma (cluster16), and transarterial interventional therapy (cluster17) are hot topics and trends in the field.</p><fig position="float" id="F13"><label>Figure 13.</label><caption><p>Clustering map of co-cited literature.</p></caption><graphic xlink:href="medi-104-e42015-g013" position="float"/></fig><fig position="float" id="F14"><label>Figure 14.</label><caption><p>Co-cited literature volcano map.</p></caption><graphic xlink:href="medi-104-e42015-g014" position="float"/></fig></sec><sec><title>3.5. Keyword analysis</title><p>By analyzing keywords, we can quickly understand the situation and development direction of a field. According to the co-occurrence of keywords in VOSwiever, the most popular keyword was sorafenib (501), followed by expression (389), therapy (246), open-label (242), and angiogenesis (240) (Table <xref rid="T7" ref-type="table">7</xref> and Figs. <xref rid="F15" ref-type="fig">15</xref> and <xref rid="F16" ref-type="fig">16</xref>). We removed useless keywords and constructed a network containing 174 keywords with at least 28 occurrences, yielding a total of 4 different clusters. Cluster 1 (red) had 74 keywords including expression, growth, pathway, protein, c-met, apoptosis, autophagy, design, factor receptor, discovery, invasion, migration, stat3, resistance, target, protect, mechanism, overexpression, potent, proliferation, and oxidative stress. Group 2 (green) has 36 keywords, including adverse events, blockade, combination, diagnosis, efficacy, immune checkpoint inhibitor, management, prognosis, resection, safety, systemic therapy, tumor microenvironment, and 1st-line therapy. Group 3 contains 35 keywords (in blue) including advanced hepatocellular carcinoma, angiogenesis, dasatinib, imatinib, meta analysis, hepatoxicity, pharmacokinetics, toxicity, vegf, and p-glycoprotein. Group 4 contains 29 keywords (yellow), including survival, chemotherapy, mutation, gene, acquired resistance, cisplatin, open label, survival, sensitivity, and Japanese patient. We plotted a volcano map via CiteSpace to visualize the research hotspots over time (Figs. <xref rid="F17" ref-type="fig">17</xref> and <xref rid="F18" ref-type="fig">18</xref>).</p><table-wrap position="float" id="T7"><label>Table 7</label><caption><p>Table of high-frequency keywords.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Rank</th><th align="center" rowspan="1" colspan="1">Keyword</th><th align="center" rowspan="1" colspan="1">Counts</th><th align="center" rowspan="1" colspan="1">Rank</th><th align="center" rowspan="1" colspan="1">Keyword</th><th align="center" rowspan="1" colspan="1">Counts</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">Sorafenib</td><td align="center" rowspan="1" colspan="1">501</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">Growth-factor receptor</td><td align="center" rowspan="1" colspan="1">209</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">Expression</td><td align="center" rowspan="1" colspan="1">389</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">Inhibitor</td><td align="center" rowspan="1" colspan="1">190</td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">Therapy</td><td align="center" rowspan="1" colspan="1">246</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">Tyrosine kinase</td><td align="center" rowspan="1" colspan="1">187</td></tr><tr><td align="left" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">Open-label</td><td align="center" rowspan="1" colspan="1">242</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">Survival</td><td align="center" rowspan="1" colspan="1">185</td></tr><tr><td align="left" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">Angiogenesis</td><td align="center" rowspan="1" colspan="1">240</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">Growth</td><td align="center" rowspan="1" colspan="1">180</td></tr><tr><td align="left" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">Double-blind</td><td align="center" rowspan="1" colspan="1">223</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">Apoptosis</td><td align="center" rowspan="1" colspan="1">176</td></tr><tr><td align="left" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">Chemotherapy</td><td align="center" rowspan="1" colspan="1">220</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">Activation</td><td align="center" rowspan="1" colspan="1">175</td></tr><tr><td align="left" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">Endothelial growth-factor</td><td align="center" rowspan="1" colspan="1">217</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">Targeted therapy</td><td align="center" rowspan="1" colspan="1">173</td></tr><tr><td align="left" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">Gefitinib</td><td align="center" rowspan="1" colspan="1">214</td><td align="center" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">Efficacy</td><td align="center" rowspan="1" colspan="1">155</td></tr><tr><td align="left" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">Resistance</td><td align="center" rowspan="1" colspan="1">214</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">Erlotinib</td><td align="center" rowspan="1" colspan="1">151</td></tr></tbody></table></table-wrap><fig position="float" id="F15"><label>Figure 15.</label><caption><p>High-frequency keyword network map.</p></caption><graphic xlink:href="medi-104-e42015-g015" position="float"/></fig><fig position="float" id="F16"><label>Figure 16.</label><caption><p>Keyword density chart.</p></caption><graphic xlink:href="medi-104-e42015-g016" position="float"/></fig><fig position="float" id="F17"><label>Figure 17.</label><caption><p>Keyword clustering volcano map.</p></caption><graphic xlink:href="medi-104-e42015-g017" position="float"/></fig><fig position="float" id="F18"><label>Figure 18.</label><caption><p>Keyword clustering map.</p></caption><graphic xlink:href="medi-104-e42015-g018" position="float"/></fig></sec><sec><title>3.6. Co-cited references and keywords</title><p>Using CiteSpace, we came up with the 50 most reliable citation bursts for tyrosinase inhibitors in liver cancer applications. One of the most cited references (55.32) is &#x0201c;Sorafenib in Advanced Hepatocellular Carcinoma&#x0201d; published in The New England Journal of Medicine homepage, which was first authored by Llovet JM, the article concluded that there is no effective systemic therapy for patients with advanced HCC. In this multicenter, phase III, double-blind, placebo-controlled trial, we randomly assigned 602 patients with advanced HCC who had not received prior systemic therapy to receive sorafenib (at a dose of 400&#x02009;mg twice daily) or placebo. The primary outcomes were OS and time to symptom progression. In the second planned interim analysis, there were 321 deaths and the study was stopped as a result. Median OS was 10.7 months in the sorafenib group and 7.9 months in the placebo group (hazard ratio 0.69 in the sorafenib group; 95% confidence interval 0.55&#x02013;0.87; <italic toggle="yes">P</italic>&#x02005;&#x0003c;&#x02005;.001). The median time to symptom progression was not significantly different between the 2 groups (4.1 and 4.9 months, respectively; <italic toggle="yes">P</italic>&#x02005;=&#x02005;.77). The median time to radiological progression was 5.5 months in the sorafenib group and 2.8 months in the placebo group (<italic toggle="yes">P</italic>&#x02005;&#x0003c;&#x02005;.001). Seven patients (2%) in the sorafenib group and 2 patients (1%) in the placebo group showed partial response, and no patients showed complete response. In patients with advanced HCC, median survival and time to radiological progression were nearly 3 months longer in patients treated with sorafenib than in those treated with placebo (<ext-link xlink:href="https://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link> number: NCT00105443). Forty-nine of the 50 references were published between 2004 and 2023, suggesting that these papers have been cited frequently over the last 20 years. Importantly, 19 of these papers are currently at peak citation (Fig. <xref rid="F19" ref-type="fig">19</xref>), implying that tyrosinase inhibitors in liver cancer will continue to be of interest in the future.</p><fig position="float" id="F19"><label>Figure 19.</label><caption><p>Cited literature emergence map.</p></caption><graphic xlink:href="medi-104-e42015-g019" position="float"/></fig><p>Among the 659 strongest mutated keywords in the field, we focused on the 50 keywords with the strongest mutations (Fig. <xref rid="F20" ref-type="fig">20</xref>), which represent the current research hotspots in the field and represent possible future research directions.</p><fig position="float" id="F20"><label>Figure 20.</label><caption><p>Keyword emergence map.</p></caption><graphic xlink:href="medi-104-e42015-g020" position="float"/></fig></sec></sec><sec sec-type="discussion"><title>4. Discussion</title><p>In recent years, the incidence and mortality of primary liver cancer have been gradually increasing. Most patients with HCC are already in the middle and advanced stages when diagnosed, losing the chance of surgery, and the survival prognosis is poor, and systemic therapy and local therapy are the main treatment options for middle and advanced HCC.<sup>[<xref rid="R17" ref-type="bibr">17</xref>]</sup></p><p>The progression of HCC is associated with an abnormal microenvironment of hepatocyte regeneration.<sup>[<xref rid="R18" ref-type="bibr">18</xref>]</sup> The development and progression of HCC involves a combination of factors, especially chronic viral hepatitis and nonviral hepatitis; among them, hepatitis B virus and hepatitis C virus are the main causes of cirrhosis and the progression to HCC. In addition, obesity, alcoholism, diabetes mellitus, and dyslipidemia, which can cause inflammatory reactions or hepatic steatosis, are all etiological factors inducing the development of HCC.<sup>[<xref rid="R19" ref-type="bibr">19</xref>&#x02013;<xref rid="R21" ref-type="bibr">21</xref>]</sup></p><p>Multi-TKIs have been used in the treatment of HCC since 2007, and in the 2007 SHARP trial evaluating sorafenib for the treatment of HCC, patients in the placebo group had an OS of 7.9 months, which was prolonged to 10.7 months in the sorafenib group.<sup>[<xref rid="R22" ref-type="bibr">22</xref>]</sup> The drug&#x02019;s safety and moderate efficacy were validated in patients in the Asia-Pacific region, which led to the approval of sorafenib as a first-line agent for the treatment of advanced unresectable HCC.<sup>[<xref rid="R23" ref-type="bibr">23</xref>]</sup> In 2018, The Lancet published a phase III clinical study of lenvatinib versus sorafenib for the first-line treatment of unresectable HCC (the REFLECT study). The results showed that the OS of lenvatinib treatment group was noninferior to that of sorafenib, while it was significantly better than sorafenib in terms of progression-free survival (PFS), time to disease progression, and objective remission rate (ORR). Moreover, the efficacy of lenvatinib in Chinese patients with HCC, especially hepatitis B virus-associated HCC, was significantly better than sorafenib, with ORR, PFS, time to disease progression, and OS being 2.6-fold, 2.6-fold, 3.0-fold, and 1.5-fold higher than that of sorafenib, respectively, suggesting that lenvatinib is more suitable for Chinese patients with HCC.<sup>[<xref rid="R15" ref-type="bibr">15</xref>]</sup> Lenvatinib mainly delays HCC progression by inhibiting VEGFRs (VEGFR1, VEGFR2, and VEGFR3) and FGFRs (FGFR1, FGFR2, FGFR3, and FGFR4). The results of the LEAP-002 study presented at the European Society for Medical Oncology Congress 2022<sup>[<xref rid="R24" ref-type="bibr">24</xref>]</sup> showed that the median OS of the lenvatinib treatment group reached 19.0 months, which is the longest median OS for single-agent, first-line treatment of unresectable HCC at this point in time; and the ORR (mRECIST by BICR) of 34.1% also refreshed the efficacy data for single-agent treatment.</p><p>In addition, multi-TKIs such as lenvatinib can release the immunosuppressive effect caused by the vascular endothelial growth factor pathway, and release the inhibitory effect on the secretion of interferon-&#x003b3; and granzyme B, thus enhancing the killing effect of cytotoxic T cells and the presentation effect of antigen-presenting cells.<sup>[<xref rid="R25" ref-type="bibr">25</xref>,<xref rid="R26" ref-type="bibr">26</xref>]</sup> On the other hand, lenvatinib can enhance the efficacy of programmed cell death 1 (PD-1) inhibitors by targeting FGFR 4 to reduce the level of programmed cell death receptor-ligand 1 in HCC cells, and regulate the differentiation of T cells.<sup>[<xref rid="R27" ref-type="bibr">27</xref>,<xref rid="R28" ref-type="bibr">28</xref>]</sup> HCC-derived CSF1 can convert macrophages to an M2 phenotype to drive immune escape and anti-PD-1 tolerance,<sup>[<xref rid="R29" ref-type="bibr">29</xref>]</sup> but lenvatinib can block the PKC&#x003b1;/ZFP64/CSF1 axis to reset the tumor microenvironment and restore sensitivity to anti-PD-1.<sup>[<xref rid="R30" ref-type="bibr">30</xref>]</sup> However, studies have shown that drug resistance and adverse effects of lenvatinib greatly hinder the efficacy of clinical treatment of HCC,<sup>[<xref rid="R31" ref-type="bibr">31</xref>]</sup> and the use of targeted agents alone not only fails to achieve the desired effect, but also the adverse effects brought about by it are an additional burden for patients, so combination therapy is a trend in clinical treatment of HCC,<sup>[<xref rid="R32" ref-type="bibr">32</xref>]</sup> to improve the response rate of tumors to treatment, prolong PFS and OS, and specific combination therapies need to be evaluated for effectiveness and safety through clinical trials.</p></sec><sec><title>5. Conclusion</title><p>In this study, we evaluated the information of literature from different years, countries, institutions, authors, disciplines, and journals by detailed bibliometric analysis of TKIs and HCC and analyzed the topic development and future research hotspots. Our study found that the field has been receiving attention since 2004. Our study provides basic information on research in the field and identifies potential partners for interested researchers. The current research hotspots mainly include the study of inflammatory mechanisms, immune mechanisms, related diseases, and related cytokines. The application of TKIs for liver cancer treatment and TK combination with multiple therapeutic regimens are at the forefront of research in this area and are emerging.</p></sec><sec><title>Author contributions</title><p><bold>Data curation:</bold> Hejun Mao.</p><p><bold>Writing &#x02013; original draft:</bold> Wurihan Wu.</p><p><bold>Resources:</bold> Jian Song.</p><p><bold>Software:</bold> Jian Song.</p><p><bold>Funding acquisition:</bold> Fan Yang.</p><p><bold>Supervision:</bold> Fan Yang.</p><p><bold>Visualization:</bold> Fan Yang.</p></sec></body><back><fn-group><fn fn-type="abbr"><p>
<def-list><title>Abbreviations:</title><def-item><term>APHP</term><def><p>Assistance Publique Hopitaux Paris</p></def></def-item><def-item><term>FGFR</term><def><p>fibroblast growth factor receptor</p></def></def-item><def-item><term>HCC</term><def><p>hepatocellular carcinoma</p></def></def-item><def-item><term>ORR</term><def><p>objective response rate</p></def></def-item><def-item><term>OS</term><def><p>overall survival</p></def></def-item><def-item><term>PD-1</term><def><p>programmed cell death 1</p></def></def-item><def-item><term>PFS</term><def><p>progression-free survival</p></def></def-item><def-item><term>RTKs</term><def><p>receptor tyrosine kinases</p></def></def-item><def-item><term>TKI</term><def><p>tyrosine kinase inhibitors</p></def></def-item><def-item><term>TKs</term><def><p>tyrosine kinases</p></def></def-item><def-item><term>VEGFR</term><def><p>vascular endothelial growth factor receptor</p></def></def-item><def-item><term>WoSCC</term><def><p>Web of Science&#x02122; Core Collection</p></def></def-item></def-list>
</p></fn></fn-group><fn-group><fn fn-type="financial-disclosure"><p>This work was supported by Inner Mongolia Medical University Postgraduate Talent Excellence Program (NO. YKD2023ZY001).</p></fn><fn fn-type="COI-statement"><p>The authors have no conflicts of interest to disclose.</p></fn><fn fn-type="other"><p>The datasets generated during and/or analyzed during the current study are available from the corresponding author upon reasonable request.</p></fn><fn fn-type="other"><p>How to cite this article: Wu W, Mao H, Song J, Yang F. Bibliometric analysis of hepatocellular carcinoma and tyrosine kinase inhibitors. Medicine 2025;104:20(e42015).</p></fn><fn fn-type="equal"><p>WW and HM contributed to this article equally.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>[1]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>M</given-names></name><name><surname>Sarkar</surname><given-names>D</given-names></name></person-group>. <article-title>HCC-related lncRNAs: roles and mechanisms.</article-title>
<source>Int J Mol Sci</source>. <year>2024</year>;<volume>25</volume>:<fpage>597</fpage>.<pub-id pub-id-type="pmid">38203767</pub-id>
</mixed-citation></ref><ref id="R2"><label>[2]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>D</given-names></name></person-group>. <article-title>Tumor microenvironment as a therapeutic target in cancer.</article-title>
<source>Pharmacol Ther</source>. <year>2021</year>;<volume>221</volume>:<fpage>107753</fpage>.<pub-id pub-id-type="pmid">33259885</pub-id>
</mixed-citation></ref><ref id="R3"><label>[3]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdelrahim</surname><given-names>M</given-names></name><name><surname>Esmail</surname><given-names>A</given-names></name><name><surname>Saharia</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Utilization of immunotherapy for the treatment of hepatocellular carcinoma in the peri-transplant setting: transplant oncology view.</article-title>
<source>Cancers (Basel)</source>. <year>2022</year>;<volume>14</volume>:<fpage>1760</fpage>.<pub-id pub-id-type="pmid">35406533</pub-id>
</mixed-citation></ref><ref id="R4"><label>[4]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Mattia</surname><given-names>E</given-names></name><name><surname>Cecchin</surname><given-names>E</given-names></name><name><surname>Guardascione</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.</article-title>
<source>World J Gastroenterol</source>. <year>2019</year>;<volume>25</volume>:<fpage>3870</fpage>&#x02013;<lpage>96</lpage>.<pub-id pub-id-type="pmid">31413525</pub-id>
</mixed-citation></ref><ref id="R5"><label>[5]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paul</surname><given-names>MK</given-names></name><name><surname>Mukhopadhyay</surname><given-names>AK</given-names></name></person-group>. <article-title>Tyrosine kinase&#x02014;role and significance in cancer.</article-title>
<source>Int J Med Sci</source>. <year>2004</year>;<volume>1</volume>:<fpage>101</fpage>&#x02013;<lpage>15</lpage>.<pub-id pub-id-type="pmid">15912202</pub-id>
</mixed-citation></ref><ref id="R6"><label>[6]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abou-Fay&#x000e7;al</surname><given-names>C</given-names></name><name><surname>Hatat</surname><given-names>AS</given-names></name><name><surname>Gazzeri</surname><given-names>S</given-names></name><name><surname>Eymin</surname><given-names>B</given-names></name></person-group>. <article-title>Splice variants of the RTK family: their role in tumour progression and response to targeted therapy.</article-title>
<source>Int J Mol Sci</source>. <year>2017</year>;<volume>18</volume>:<fpage>383</fpage>.<pub-id pub-id-type="pmid">28208660</pub-id>
</mixed-citation></ref><ref id="R7"><label>[7]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name></person-group>. <article-title>Targeting epidermal growth factor receptor for cancer treatment: abolishing both kinase-dependent and kinase-independent functions of the receptor.</article-title>
<source>Pharmacol Rev</source>. <year>2023</year>;<volume>75</volume>:<fpage>1218</fpage>&#x02013;<lpage>32</lpage>.<pub-id pub-id-type="pmid">37339882</pub-id>
</mixed-citation></ref><ref id="R8"><label>[8]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>M</given-names></name><name><surname>Long</surname><given-names>J</given-names></name><name><surname>Yao</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>METTL1-mediated m7G tRNA modification promotes lenvatinib resistance in hepatocellular carcinoma.</article-title>
<source>Cancer Res</source>. <year>2023</year>;<volume>83</volume>:<fpage>89</fpage>&#x02013;<lpage>102</lpage>.<pub-id pub-id-type="pmid">36102722</pub-id>
</mixed-citation></ref><ref id="R9"><label>[9]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>CC</given-names></name><name><surname>Suen</surname><given-names>KM</given-names></name><name><surname>Lidster</surname><given-names>J</given-names></name><name><surname>Ladbury</surname><given-names>JE</given-names></name></person-group>. <article-title>The emerging role of receptor tyrosine kinase phase separation in cancer.</article-title>
<source>Trends Cell Biol</source>. <year>2024</year>;<volume>34</volume>:<fpage>371</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">37777392</pub-id>
</mixed-citation></ref><ref id="R10"><label>[10]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ninkov</surname><given-names>A</given-names></name><name><surname>Frank</surname><given-names>JR</given-names></name><name><surname>Maggio</surname><given-names>LA</given-names></name></person-group>. <article-title>Bibliometrics: methods for studying academic publishing.</article-title>
<source>Perspect Med Educ</source>. <year>2022</year>;<volume>11</volume>:<fpage>173</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">34914027</pub-id>
</mixed-citation></ref><ref id="R11"><label>[11]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>KL</given-names></name><name><surname>Jia</surname><given-names>YB</given-names></name><name><surname>Liu</surname><given-names>XJ</given-names></name><etal/></person-group>. <article-title>Bibliometrics analysis based on the Web of Science: current trends and perspective of gastric organoid during 2010-2023.</article-title>
<source>World J Gastroenterol</source>. <year>2024</year>;<volume>30</volume>:<fpage>969</fpage>&#x02013;<lpage>83</lpage>.<pub-id pub-id-type="pmid">38516239</pub-id>
</mixed-citation></ref><ref id="R12"><label>[12]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>N</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>A bibliometric analysis of T cell and atherosclerosis.</article-title>
<source>Front Immunol</source>. <year>2022</year>;<volume>13</volume>:<fpage>948314</fpage>.<pub-id pub-id-type="pmid">36311729</pub-id>
</mixed-citation></ref><ref id="R13"><label>[13]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Eck</surname><given-names>NJ</given-names></name><name><surname>Waltman</surname><given-names>L</given-names></name></person-group>. <article-title>Software survey: VOSviewer, a computer program for bibliometric mapping.</article-title>
<source>Scientometrics</source>. <year>2010</year>;<volume>84</volume>:<fpage>523</fpage>&#x02013;<lpage>38</lpage>.<pub-id pub-id-type="pmid">20585380</pub-id>
</mixed-citation></ref><ref id="R14"><label>[14]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>C</given-names></name></person-group>. <article-title>Searching for intellectual turning points: progressive knowledge domain visualization.</article-title>
<source>Proc Natl Acad Sci USA</source>. <year>2004</year>;<volume>101 Suppl 1</volume>(<issue>Suppl 1</issue>):<fpage>5303</fpage>&#x02013;<lpage>10</lpage>.<pub-id pub-id-type="pmid">14724295</pub-id>
</mixed-citation></ref><ref id="R15"><label>[15]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kudo</surname><given-names>M</given-names></name><name><surname>Finn</surname><given-names>RS</given-names></name><name><surname>Qin</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.</article-title>
<source>Lancet</source>. <year>2018</year>;<volume>391</volume>:<fpage>1163</fpage>&#x02013;<lpage>73</lpage>.<pub-id pub-id-type="pmid">29433850</pub-id>
</mixed-citation></ref><ref id="R16"><label>[16]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruix</surname><given-names>J</given-names></name><name><surname>Qin</surname><given-names>S</given-names></name><name><surname>Merle</surname><given-names>P</given-names></name><etal/></person-group>.; <collab>RESORCE Investigators</collab>. <article-title>Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.</article-title>
<source>Lancet</source>. <year>2017</year>;<volume>389</volume>:<fpage>56</fpage>&#x02013;<lpage>66</lpage>.<pub-id pub-id-type="pmid">27932229</pub-id>
</mixed-citation></ref><ref id="R17"><label>[17]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taniguchi</surname><given-names>H</given-names></name></person-group>. <article-title>Liver cancer 2.0.</article-title>
<source>Int J Mol Sci</source>. <year>2023</year>;<volume>24</volume>:<fpage>17275</fpage>.<pub-id pub-id-type="pmid">38139103</pub-id>
</mixed-citation></ref><ref id="R18"><label>[18]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ganesan</surname><given-names>P</given-names></name><name><surname>Kulik</surname><given-names>LM</given-names></name></person-group>. <article-title>Hepatocellular carcinoma: new developments.</article-title>
<source>Clin Liver Dis</source>. <year>2023</year>;<volume>27</volume>:<fpage>85</fpage>&#x02013;<lpage>102</lpage>.<pub-id pub-id-type="pmid">36400469</pub-id>
</mixed-citation></ref><ref id="R19"><label>[19]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>ZJ</given-names></name><name><surname>Tsilimigras</surname><given-names>DI</given-names></name><name><surname>Ruff</surname><given-names>SM</given-names></name><etal/></person-group>. <article-title>Management of hepatocellular carcinoma: a review.</article-title>
<source>JAMA Surg</source>. <year>2023</year>;<volume>158</volume>:<fpage>410</fpage>&#x02013;<lpage>20</lpage>.<pub-id pub-id-type="pmid">36790767</pub-id>
</mixed-citation></ref><ref id="R20"><label>[20]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mcglynn</surname><given-names>KA</given-names></name><name><surname>Petrick</surname><given-names>JL</given-names></name><name><surname>El-Serag</surname><given-names>HB</given-names></name></person-group>. <article-title>Epidemiology of hepatocellular carcinoma.</article-title>
<source>Hepatology</source>. <year>2021</year>;<volume>73 Suppl 1</volume>(<issue>Suppl 1</issue>):<fpage>4</fpage>&#x02013;<lpage>13</lpage>.</mixed-citation></ref><ref id="R21"><label>[21]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>D</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Fan</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>Q</given-names></name></person-group>. <article-title>Clinical practice guidelines and real-life practice in hepatocellular carcinoma: a Chinese perspective.</article-title>
<source>Clin Mol Hepatol</source>. <year>2023</year>;<volume>29</volume>:<fpage>206</fpage>&#x02013;<lpage>16</lpage>.<pub-id pub-id-type="pmid">36545708</pub-id>
</mixed-citation></ref><ref id="R22"><label>[22]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Llovet</surname><given-names>JM</given-names></name><name><surname>Ricci</surname><given-names>S</given-names></name><name><surname>Mazzaferro</surname><given-names>V</given-names></name><etal/></person-group>.; <collab>SHARP Investigators Study Group</collab>. <article-title>Sorafenib in advanced hepatocellular carcinoma.</article-title>
<source>N Engl J Med</source>. <year>2008</year>;<volume>359</volume>:<fpage>378</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="pmid">18650514</pub-id>
</mixed-citation></ref><ref id="R23"><label>[23]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>FH</given-names></name><name><surname>Ye</surname><given-names>QF</given-names></name><name><surname>Miao</surname><given-names>XY</given-names></name><etal/></person-group>. <article-title>Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma.</article-title>
<source>Theranostics</source>. <year>2021</year>;<volume>11</volume>:<fpage>5464</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="pmid">33859758</pub-id>
</mixed-citation></ref><ref id="R24"><label>[24]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ducreux</surname><given-names>M</given-names></name><name><surname>Abou-Alfa</surname><given-names>GK</given-names></name><name><surname>Bekaii-Saab</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022.</article-title>
<source>ESMO Open</source>. <year>2023</year>;<volume>8</volume>:<fpage>101567</fpage>.<pub-id pub-id-type="pmid">37263081</pub-id>
</mixed-citation></ref><ref id="R25"><label>[25]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bao</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>J</given-names></name><name><surname>Han</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Tyrosine kinase Btk is required for NK cell activation.</article-title>
<source>J Biol Chem</source>. <year>2012</year>;<volume>287</volume>:<fpage>23769</fpage>&#x02013;<lpage>78</lpage>.<pub-id pub-id-type="pmid">22589540</pub-id>
</mixed-citation></ref><ref id="R26"><label>[26]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rivi&#x000e8;re</surname><given-names>E</given-names></name><name><surname>Pascaud</surname><given-names>J</given-names></name><name><surname>Tchitchek</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Salivary gland epithelial cells from patients with Sj&#x000f6;gren&#x02019;s syndrome induce B-lymphocyte survival and activation.</article-title>
<source>Ann Rheum Dis</source>. <year>2020</year>;<volume>79</volume>:<fpage>1468</fpage>&#x02013;<lpage>77</lpage>.<pub-id pub-id-type="pmid">32843324</pub-id>
</mixed-citation></ref><ref id="R27"><label>[27]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yi</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Lin</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>Lenvatinib targets FGF receptor 4 to enhance antitumor immune response of anti-programmed cell death-1 in HCC.</article-title>
<source>Hepatology</source>. <year>2021</year>;<volume>74</volume>:<fpage>2544</fpage>&#x02013;<lpage>60</lpage>.<pub-id pub-id-type="pmid">34036623</pub-id>
</mixed-citation></ref><ref id="R28"><label>[28]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arance</surname><given-names>A</given-names></name><name><surname>De La Cruz-Merino</surname><given-names>L</given-names></name><name><surname>Petrella</surname><given-names>TM</given-names></name><etal/></person-group>. <article-title>Phase II LEAP-004 study of lenvatinib plus pembrolizumab for melanoma with confirmed progression on a programmed cell death protein-1 or programmed death ligand 1 inhibitor given as monotherapy or in combination.</article-title>
<source>J Clin Oncol</source>. <year>2023</year>;<volume>41</volume>:<fpage>75</fpage>&#x02013;<lpage>85</lpage>.<pub-id pub-id-type="pmid">35867951</pub-id>
</mixed-citation></ref><ref id="R29"><label>[29]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sehgal</surname><given-names>A</given-names></name><name><surname>Irvine</surname><given-names>KM</given-names></name><name><surname>Hume</surname><given-names>DA</given-names></name></person-group>. <article-title>Functions of macrophage colony-stimulating factor (CSF1) in development, homeostasis, and tissue repair.</article-title>
<source>Semin Immunol</source>. <year>2021</year>;<volume>54</volume>:<fpage>101509</fpage>.<pub-id pub-id-type="pmid">34742624</pub-id>
</mixed-citation></ref><ref id="R30"><label>[30]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>CY</given-names></name><name><surname>Zhu</surname><given-names>MX</given-names></name><name><surname>Zhang</surname><given-names>PF</given-names></name><etal/></person-group>. <article-title>PKC&#x003b1;/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma.</article-title>
<source>J Hepatol</source>. <year>2022</year>;<volume>77</volume>:<fpage>163</fpage>&#x02013;<lpage>76</lpage>.<pub-id pub-id-type="pmid">35219791</pub-id>
</mixed-citation></ref><ref id="R31"><label>[31]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>Q</given-names></name><name><surname>Huang</surname><given-names>D</given-names></name></person-group>. <article-title>Resistance of lenvatinib in hepatocellular carcinoma.</article-title>
<source>Curr Cancer Drug Targets</source>. <year>2022</year>;<volume>22</volume>:<fpage>865</fpage>&#x02013;<lpage>78</lpage>.<pub-id pub-id-type="pmid">36267045</pub-id>
</mixed-citation></ref><ref id="R32"><label>[32]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finn</surname><given-names>RS</given-names></name><name><surname>Ikeda</surname><given-names>M</given-names></name><name><surname>Zhu</surname><given-names>AX</given-names></name><etal/></person-group>. <article-title>Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma.</article-title>
<source>J Clin Oncol</source>. <year>2020</year>;<volume>38</volume>:<fpage>2960</fpage>&#x02013;<lpage>70</lpage>.<pub-id pub-id-type="pmid">32716739</pub-id>
</mixed-citation></ref></ref-list></back></article>